All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
This is a phase I trial. The purpose of the study is to observe the safety, efficacy (good or bad) and determine the maximum dose of Lintuzumab-Ac225 that can be given to patients with multiple myeloma like you without causing bad effects.
A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects with Multiple Myeloma
It will see if AMG 424 is safe and tolerable and whether it causes any side effects. This study will also look at what doses of AMG 424 are safe for people to take and what the effect on Multiple Myeloma is.
The study will be conducted in 2 Parts: Part 1 (Dose Exploration) and Part 2 (Dose Expansion).
• Part 1 of the study will enroll 1-4 people at the same dose level starting with the selected starting dose. If the selected dose is tolerated, the dose will then be increased for each new group of 1-4 people to find a maximum tolerated dose of AMG 424 that can be safely given to people with Multiple Myeloma.
• Part 2 of the study will see if the AMG 424 dose selected in Part 1 is both safe and effective in subjects with Multiple Myeloma who also have standard or low risk cytogenetics as well as those with high risk cytogenetics.
o Cytogenetics involves testing samples of tissue, blood, or bone marrow in a laboratory to look for changes in chromosomes, which are made of DNA. Certain changes in chromosomes can be used to predict the course of the disease or prognosis
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients with Advanced Solid Tumors
An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 Naïve and PD-(L)1 Pretreated Patient Populations with Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy
penis, esophagus, and vulva; hepatocellular carcinoma; biliary tract carcinoma, small-cell lung cancer;
A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Nonsmall Cell Lung Cancer (NSCLC)
The vaccine, BI 1361849, also works by stimulating the body’s immune system to fight and destroy cancer cells. There are six different ingredients in the vaccine that each produce a different antibody response to tumor cells. The vaccine is given through an injection into your skin.